

BIOMARIN PHARMACEUTICAL INC  
Form 4  
April 01, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BIENAIME JEAN JACQUES**

2. Issuer Name and Ticker or Trading Symbol  
**BIOMARIN PHARMACEUTICAL INC [BMRN]**

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Executive Officer

(Last) (First) (Middle)  
**C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.**  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
**03/28/2014**

**SAN RAFAEL, CA 94901**  
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D) Code V Amount (D) Price			Shares held by
Common Stock	03/28/2014	03/28/2014	M	2,000 A \$ 12.99	48,740	I	Bienaime Family Trust <sup>(1)</sup>
Common Stock					194,520	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy Common Stock)	\$ 12.99	03/28/2014	03/28/2014	M	2,000	11/11/2006	05/10/2016	Common Stock	2,000
Stock Option (right to buy Common Stock)	\$ 12.99					11/11/2006	05/10/2016	Common Stock	10,000
Stock Option (right to buy Common Stock)	\$ 12.99					11/11/2006	05/10/2016	Common Stock	10,000
Stock Option (right to buy Common Stock)	\$ 12.99					11/11/2006	05/10/2016	Common Stock	10,000
Stock Option (right to buy Common Stock)	\$ 12.99					11/11/2006	05/10/2016	Common Stock	10,000

Stock)

Stock Option (right to buy Common Stock)	\$ 12.99	11/11/2006	05/10/2016	Common Stock	20,000
---	----------	------------	------------	-----------------	--------

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL, CA 94901	X		Chief Executive Officer	

## Signatures

/s/ Laura Randall Woodhead, Attorney-in-Fact	04/01/2014
<small>**Signature of Reporting Person</small>	<small>Date</small>

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The reporting person and his spouse act as trustees for the Bienaime Family Trust.

Form 4s filed by the reporting person between March 4, 2013 and February 24, 2014 (the "Prior Forms 4s") inadvertently reported as common stock indirectly owned by the reporting person on Table I options to purchase an aggregate of 60,000 shares held in trusts for the reporting person's children (the "Options") while certain of the Prior Form 4s inadvertently omitted the Options from Table II. The

(2) reporting person gifted the Options to his children's trusts on October 19, 2012 and the transactions were reported on the Form 5 filed by the reporting person on February 14, 2013. As the Options have not been exercised and remain derivative securities indirectly owned by the reporting person, the Options should not have been included in Table I in the Prior Form 4s and have been correctly listed as derivative securities on Table II of this Form 4.

(3) The reporting person's spouse is trustee of each child's trust.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.